Patient-Specific Immersed Finite Element-Difference Model of Transcatheter Aortic Valve Replacement.
Jordan A BrownJae H LeeMargaret Anne SmithDavid R WellsAaron BarrettCharles PuelzJohn P VavalleBoyce E GriffithPublished in: Annals of biomedical engineering (2022)
Transcatheter aortic valve replacement (TAVR) first received FDA approval for high-risk surgical patients in 2011 and has been approved for low-risk surgical patients since 2019. It is now the most common type of aortic valve replacement, and its use continues to accelerate. Computer modeling and simulation (CM&S) is a tool to aid in TAVR device design, regulatory approval, and indication in patient-specific care. This study introduces a computational fluid-structure interaction (FSI) model of TAVR with Medtronic's CoreValve Evolut R device using the immersed finite element-difference (IFED) method. We perform dynamic simulations of crimping and deployment of the Evolut R, as well as device behavior across the cardiac cycle in a patient-specific aortic root anatomy reconstructed from computed tomography (CT) image data. These IFED simulations, which incorporate biomechanics models fit to experimental tensile test data, automatically capture the contact within the device and between the self-expanding stent and native anatomy. Further, we apply realistic driving and loading conditions based on clinical measurements of human ventricular and aortic pressures and flow rates to demonstrate that our Evolut R model supports a physiological diastolic pressure load and provides informative clinical performance predictions.
Keyphrases
- transcatheter aortic valve replacement
- transcatheter aortic valve implantation
- aortic valve
- aortic valve replacement
- aortic stenosis
- left ventricular
- finite element
- computed tomography
- ejection fraction
- endothelial cells
- deep learning
- molecular dynamics
- heart failure
- healthcare
- image quality
- electronic health record
- blood pressure
- dual energy
- big data
- transcription factor
- pain management
- quality improvement
- contrast enhanced
- induced pluripotent stem cells
- affordable care act